Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Brief Summary: This study was to assess whether sofosbuvir in combination with ribavirin (RBV) and pegylated interferon alfa 2a (PEG) administered for 12 weeks is safe and effective in patients with hepatitis C virus (HCV) genotypes 1, 4, 5 , or 6 as assessed by the rate of sustained viral response (SVR) 12 weeks after discontinuation of therapy (SVR12).


Options:
A: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
B: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV
C: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week
D: Arm Label: Treatment A: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment B: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment C: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment D: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment E: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment F: PSI-7977 + Daclatasvir+ Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment G: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment H: PSI-7977 + BMS-790052 + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment I: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment J: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: PSI-7977; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment J: PSI-7977 + Daclatasvir + Ribavirin

Answer: B